A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva [erlotinib] or placebo following four cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for...

Trial Profile

A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva [erlotinib] or placebo following four cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for...

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2006

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2006 The expected completion date for this trial is now 1 Jan 2009.
    • 06 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top